EGRX
NASDAQEagle Pharmaceuticals Inc.
Price$2.12+0.00 (+0.00%)
2025-06-302025-10-01
News · 26 weeks10%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- PREagle Pharmaceuticals Announces Divestiture of BarhemsysWOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective option to manage this common complication. "This strategic divestitu
- PREagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights PlanWOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has adopted an amendment (the "Amendment") to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company's common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were
- PREagle Pharmaceuticals Announces Results of 2025 Annual Meeting of StockholdersWOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the "Annual Meeting") held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 1. Election of Directors Election of (i) two Class I nominees for director, Michael Graves and Richard Edlin
- PREagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial StatementsWOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that the Company's unaudited financial statements for the three and six months ended June 30, 2025, are available at https://investor.eagleus.com/events-presentations. About Eagle Pharmaceuticals, Inc.Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO®
- PREagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial StatementsWOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that the Company's unaudited financial statements for the three months ended March 31, 2025, are available at https://investor.eagleus.com/events-presentations. About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and
- PREagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal YearsWOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time. The Company is delivering a Notice of Internet Availability of Proxy Materials ("Notice") to stockholders of record as of the close of business on August 18, 2025. The proxy materials relating to the 2025 Annual Meeting of Stockholders, including the Notice, proxy information statement and proxy card, are available at www.proxyvote.com and https://investor.eagleus.com/events-presentatio
- PREagle Pharmaceuticals to Appoint Abhinav Jain to its Board of DirectorsWOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has agreed to appoint Abhinav "Abi" Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders and serve on the Board's Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain's planned appointment, Eagle entered into a cooperation agreement (the "Agreement") with Nantahala Capital Management, LLC (together with its affiliates, "Nantahala"),
- PREagle Pharmaceuticals Announces 2025 Annual Meeting DateWOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting. The Company's bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following
- PREagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® RoyaltiesWOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. ("Blue Owl") (the "Agreement"), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before transaction costs. BENDEKA is a ready-to-dilute liquid, low-volume (50 mL) and short-time ten-minute infusion formulation of bendamustine. It is approved for the treatment of chronic lymphoc
- PREagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanWOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow
- SECSEC Form 15-12G filed by Eagle Pharmaceuticals Inc.15-12G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form EFFECT filed by Eagle Pharmaceuticals Inc.EFFECT - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECEagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form RW filed by Eagle Pharmaceuticals Inc.RW - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form POS AM filed by Eagle Pharmaceuticals Inc.POS AM - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.S-8 POS - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.S-8 POS - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.S-8 POS - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.S-8 POS - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.S-8 POS - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.S-8 POS - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECEagle Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- SECSEC Form 25 filed by Eagle Pharmaceuticals Inc.25 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
- INSIDERSEC Form 3 filed by new insider Krawtschuk Christopher3 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
- SECEagle Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
EGRX FAQ
7 questionsWhat does Eagle Pharmaceuticals Inc. do?
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for...Where does EGRX stock trade?
Eagle Pharmaceuticals Inc. (EGRX) is listed on NASDAQ.What sector and industry is EGRX in?
Eagle Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Eagle Pharmaceuticals Inc. go public?
Eagle Pharmaceuticals Inc. (EGRX) completed its IPO in 2014.What are analysts saying about EGRX?
Eagle Pharmaceuticals Inc. has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Underweight with a $1700.00 price target on 2023-08-10. Recent price targets cluster around $1700.00.What companies are similar to EGRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EGRX side-by-side with any of them on Quantisnow.How can I track EGRX on Quantisnow?
Quantisnow aggregates Eagle Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EGRX to receive live email and push alerts on every new disclosure.